Click Here to return To Results

 

Alemtuzumab CARE-MS I 5-year follow-up Neurol 89:1107-1116, Havrdova, E.,et al, 2017 See this aricle in Pubmed Article Abstract Based on these data, alemtuzumab provides durable efficacy through 5 years in the absence of continuous treatment, with most patients not receiving additional courses.

Related Tags

(click to filter results - removes previous filter) alemtuzumab brain atrophy efficacy immunomodulation monoclonal antibodies MRI,abnormal multiple sclerosis multiple sclerosis,relapsing multiple sclerosis,treatment of treatment of neurologic disorder

Click Here to return To Results